Hepatocellular carcinoma (HCC, also called malignant hepatoma) is the most common type of liver cancer. Most cases of HCC are secondary to either a viral hepatitide infection (hepatitis B or C ...

Randomized controlled trials are also needed to determine whether statins can actually reduce the risk for hepatocellular ...

Hepatocellular carcinoma (HCC) represents a significant ... (APHE), present a diagnostic challenge and a significant risk of malignant transformation. The use of liver-specific contrast agents ...

Hepatocellular carcinoma is also called hepatoma or HCC ... They aren’t cancer and usually won’t become cancerous (malignant) in the future. Benign tumours do not usually need treatment. This can ...

Background: Hepatoblastoma (HBL) and hepatocellular carcinoma (HCC) are respectively the first and the second most common pediatric malignant liver tumors. The purpose of this study was to ...

Caption Hepatocellular carcinoma (HCC) is one of the deadliest malignant tumors in the world, and its incidence and mortality have increased year by year. HCC research has increasingly focused on ...

Hepatocellular carcinoma (HCC) is a major global health ... such as poor specificity for distinguishing malignant from benign tumors and difficulty in visualizing deep lesions.

Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...